WJ-39

• UNSPSC Description:

  WJ-39 is an orally active aldose reductase (AR) inhibitor. WJ-39 improves tubular damage in diabetic nephropathy rats by activating PINK1/Parkin signaling, promoting mitophagy, and attenuating apoptosis[1].

• Target Antigen:

  Aldose Reductase; Apoptosis; Mitochondrial Metabolism; Mitophagy

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Autophagy;Metabolic Enzyme/Protease

• Applications:

  Metabolism-sugar/lipid metabolism

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/wj-39.html

• Solubility:

  DMSO : ≥ 350 mg/mL

• Smiles:

  COC1=CC=C(N(CC(O[K])=O)C=C(CC2=CC=CC(Cl)=C2Cl)C3=O)C3=C1

• Molecular Weight:

  430.32

• References & Citations:

  [1]Yang L, et al. An aldose reductase inhibitor, WJ-39, ameliorates renal tubular injury in diabetic nephropathy by activating PINK1/Parkin signaling. Eur J Pharmacol. 2024 Mar 15;967:176376.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  3009908-95-3